Order byBest matchMost fresh

Zepbound, Eli Lilly and Novo Nordisk

Digest more
Top News
Overview
Highlights
Eli Lilly's Zepbound Outperforms Wegovy In New Obesity Trial, But Trump's Drug Pricing Plan Keeps Retail Traders Wary
Eli Lilly and Co's obesity drug Zepbound led to greater weight loss than Novo Nordisk's Wegovy in a head-to-head Phase 3b trial, according to data published in The New England Journal of Medicine and presented at the European Congress on Obesity.

Continue reading

Eli Lilly's Zepbound Shows Superior Weight Loss Over Novo Nordisk's Wegovy In Head-To-Head Trial
BioSpace · 1d
Lilly’s Zepbound Secures “Superior Benefit-Risk Ratio” Over Novo’s Wegovy
Eli Lilly's Zepbound outperforms Novo Nordisk's Wegovy for weight loss in trial
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day.

Continue reading

First head-to-head trial found Zepbound beats Wegovy for weight loss
New study compares Wegovy and Zepbound for the first time
Eli Lilly's Zepbound beat Novo Nordisk’s Wegovy in a big weight loss drug study
Participants who took Eli Lilly’s tirzepatide, which is sold as Zepbound, lost 50 pounds on average, while those using Novo Nordisk’s semaglutide, also known as Wegovy, lost an average of 33 pounds.

Continue reading

Eli Lilly Says Trial Patients Lost More Weight on Zepbound Than Rival’s Wegovy
Here’s how much extra weight is lost with Zepbound over Wegovy
Zepbound trims more belly fat than Wegovy, study shows
The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the rival medicines.
CVS Health Excludes Zepbound: Why Eli Lilly's 11%+ Drop Looks Overdone
Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click for why LLY growth remains strong.
MedPage Today on MSN1d
Zepbound and Wegovy Go Head to Head for Obesity: And the Winner Is ...
Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial.
Feedback